Michael Hansen, 42, from Hebburn has been disqualified as a director for 10 years after overstating the turnover of his engineering firm to claim a £40,000 Bounce Back Loan to which his business was not entitled.

Hansen was the sole director of MH Property & Engineering Services Limited, which was incorporated in 2019 and traded as a property and engineering firm from Monkton Lane in Hebburn until it went into liquidation in November 2021.

When the company’s turnover decreased during the pandemic, Hansen applied for a Bounce Back Loan to help support his business, stating the company’s turnover to be £160,000.

Bounce Back Loans were a government scheme to help businesses to stay afloat during the Covid pandemic. Companies could apply for a loan of between £2,000 and £50,000, up to a maximum of 25% of their turnover. The money was to be used for the economic benefit of the company, under the rules of the scheme.

MH Property and Engineering Limited struggled to recover the custom it lost during the pandemic and went into liquidation, owing more than £42,000 and triggering an investigation by the Insolvency Service.

Investigators discovered that during the company’s first year of trading, up to June 2020, MH Property and Engineering Limited’s turnover was £8,294 and the company had therefore received nearly £38,000 more than it had been entitled to through the Bounce Back Loan scheme.

They also found that around £14,000 had later been withdrawn or paid out of the company’s bank account, followed by a transfer of around £24,600 to Hansen himself between November 2020 and August 2021.

Hansen was unable to show investigators that the money had been used for the economic benefit of the company.

The Secretary of State for Business, Energy and Industrial Strategy accepted a disqualification undertaking from Michael Hansen after he did not dispute that he had overstated the turnover of MH Property and Engineering Services Limited to gain more than £37,900 to which it was not entitled, and had failed to make sure the money was used for the economic benefit of the company.

His disqualification started on 11 November 2022 and lasts for 10 years. The ban prevents Hansen from directly or indirectly becoming involved in the promotion, formation or management of a company, without the permission of the court.

Mike Smith, Chief Investigator of the Insolvency Service said,

Covid Support Schemes were a lifeline to businesses across the UK protecting jobs and preserving businesses.

We will not hesitate to take action against directors who have abused Covid-19 financial support like this, and Hansen’s lengthy ban should serve as a warning to others.

Michael Hansen is of Hebburn and his date of birth is November 1980.

MH Property and Engineering Limited company number 12061331.

Disqualification undertakings are the administrative equivalent of a disqualification order but do not involve court proceedings.

Persons subject to a disqualification order are bound by a range of restrictions.

Further information about the work of the Insolvency Service, and how to complain about financial misconduct.

You can also follow the Insolvency Service on:

The latest data published by the UK Health Security Agency (UKHSA) reveals that the estimated total number of serious antibiotic resistant infections in England rose by 2.2% in 2021 compared to 2020 (53,985 compared to 52,842). This is the equivalent of 148 severe antibiotic resistant infections a day in 2021.

Antibiotic resistance occurs naturally, but inappropriate usage and overuse of antibiotics can accelerate this process. Antibiotic-resistant bacteria are less likely to respond to treatment, causing serious complications, including bloodstream infections, sepsis and hospitalisation. This is why it is important to take antibiotics only when they are prescribed and necessary for the condition.

The number of severe antibiotic-resistant infections remains below pre-pandemic levels (62,422 in 2019), driven by a number of factors including changes in how NHS services were delivered and how much people contacted the NHS, as well as social behaviour (reduced social mixing and enhanced hand hygiene) during the pandemic.

In England, total antibiotic use fell by 15.1% between 2017 to 2021, from 18.8 Daily Defined Doses (DDD) per 1,000 inhabitants per day to 15.9. This means that England has exceeded the government’s National Action Plan goal to reduce prescribing by 15% by 2024 from a 2014 baseline. However, this downward trend may not be sustained unless we continue to use antibiotics appropriately and continue to drive down infections overall.

Professor Susan Hopkins, Chief Medical Advisor at UKHSA, said:

We are already seeing resistance emerge to our very newest antibiotics – innovation to find new treatments will only succeed if we use what we have responsibly. Overuse of antibiotics will mean they stop working against life threatening conditions such as sepsis.

Antibiotics won’t help the symptoms of cold, flu or coronavirus (COVID-19) – please trust your healthcare professional, take antibiotics only as prescribed, never share with others and don’t save for later. Taking antibiotics when you don’t need them puts you and your loved ones at risk of having an untreatable infection in future.

Professor Dame Jenny Harries, Chief Executive of UKHSA, said:

Antibiotic resistance is not a distant problem that we can ignore – infections caused by antibiotic resistant bacteria are killing thousands of people every year in this country and globally, as well as having a huge economic impact. As we emerge from the COVID-19 pandemic, this is a pivotal moment to maintain focus on the ‘silent pandemic’ of antibiotic resistance through our extensive surveillance and antibiotic stewardship activities.

While the number of severe antibiotic resistant infections has reduced during the pandemic compared to 2019, resistance to some key antibiotics remains high. Over two-fifths of E. coli bloodstream infections are resistant to co-amoxiclav, a key antibiotic used in the treatment of serious infections in hospital. UKHSA is also monitoring newer antibiotic therapies such as cefiderocol to identify resistance.

An initial assessment of cefiderocol susceptibility in E. coli and Pseudomonas spp. bloodstream isolates in England has already identified resistance. Investigating and understanding resistance to newer antibiotics is an important area of development.